Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Revenue (2017 - 2025)

Historic Revenue for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $9.7 million.

  • Sutro Biopharma's Revenue rose 1376.76% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.9 million, marking a year-over-year decrease of 3861.64%. This contributed to the annual value of $62.0 million for FY2024, which is 5964.18% down from last year.
  • Per Sutro Biopharma's latest filing, its Revenue stood at $9.7 million for Q3 2025, which was up 1376.76% from $63.7 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Revenue ranged from a high of $113.7 million in Q4 2023 and a low of $5.7 million during Q1 2025
  • Over the past 5 years, Sutro Biopharma's median Revenue value was $13.0 million (recorded in 2024), while the average stood at $21.9 million.
  • As far as peak fluctuations go, Sutro Biopharma's Revenue skyrocketed by 121743.51% in 2023, and later plummeted by 8697.78% in 2024.
  • Sutro Biopharma's Revenue (Quarter) stood at $10.7 million in 2021, then decreased by 18.98% to $8.6 million in 2022, then surged by 1217.44% to $113.7 million in 2023, then plummeted by 86.98% to $14.8 million in 2024, then crashed by 34.55% to $9.7 million in 2025.
  • Its Revenue stands at $9.7 million for Q3 2025, versus $63.7 million for Q2 2025 and $5.7 million for Q1 2025.